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The paper describes how the Advisory Committee on Communicable Diseases (ACCD) in Sri Lanka
addresses new challenges by ensuring participatory, collective and transparent decision-making through
a broad representation of stakeholders. The Committee, which is more than 40 years old, differs fromri Lanka
many other national immunization advisory committees, since it has a broad mandate to deal with all
communicable diseases, including those for which there are no vaccines, and addresses such areas as
disease surveillance and health system improvements, in addition to vaccination-related issues. The
Committee has 38 members. Unlike in some countries, ACCD recommendations are legally binding for
all public sector health providers. The paper provides several examples of recent recommendations and
e Com
. factors that inﬂuenced th
be improved.
. Introduction
Sri Lanka’s Expanded Programme on Immunization (EPI), intro-
uced in 1977 [1], achieved Universal Childhood Immunization
tatus (coverage of more than 80%) for all EPI vaccines within 12
ears. Today, the program – now called the National Programme of
mmunization (NPI) – has achieved an immunization coverage rate
f over 95% for all infant immunizations, resulting in an extremely
ow incidence of EPI-targeted diseases [2,3]. The country has also
een a pioneer in the Asian region in introducing several new vac-
ines into its national immunization program, including Japanese
ncephalitis, rubella (alone or with measles), tetanus–diphtheria
or older children, hepatitis B and Haemophilus inﬂuenza type b
Hib). Due to the success of the program in reducing the morbidity
nd mortality of vaccine-preventable diseases, the Sri Lankan gov-
rnment has identiﬁed and earmarked the NPI as an essential area
or investment for national development [4].
After ensuring high universal vaccine coverage, the focus of the
rogram has now shifted towards improving the quality of immu-
ization services, strengthening the vaccine cold chain, improving
Abbreviations: AEFI, adverse effects following immunizations; ACCD, Advisory
ommittee on Communicable Diseases; EPI, Expanded Programme on Immu-
ization; GAVI, Global Alliance for Vaccine and Immunization; Hib, Haemophilus
nﬂuenza type b; JMOs, Judicial Medical Ofﬁcers; MR, measles–rubella; MOH, Min-
stry of Health; NIDs, National Immunization Days; NPI, National Programme of
mmunization; SNIDs, Sub-National Immunization Days; UNICEF, United Nations
hildren’s Fund; WHO, World Health Organization.
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the accessibility of hard-to-reachpopulations tovaccines, strength-
ening surveillance of adverse effects following immunizations
(AEFI) as well as surveillance of vaccine-preventable diseases [5].
The public also has been increasingly concerned about the qual-
ity and safety of vaccines provided through theNPI. These concerns
are likely the result of the low incidence of vaccine-preventable
diseases in the country and the public’s access to often unfounded,
negative media coverage of AEFI. The nation’s highly literate pop-
ulation (with a literacy rate of >90%) has a tendency to follow,
in particular, stories in the media about serious, life-threatening
vaccine-related adverse events. These developments have threat-
ened the acceptability and credibility of the NPI.
Consequently, transparency and the collective responsibility of
evidence-based decision-making that involves broad representa-
tion of key stakeholders are necessary for the continued success
of the NPI. In this paper, we describe the Advisory Committee on
Communicable Diseases (ACCD) which makes recommendations
concerning all major changes in the NPI, including the introduction
of new vaccines, and which has representation from a broad spec-
trum of stakeholders. The role of the ACCD in decision-making has
been a key evolutionary step in the development of the country’s
well-regarded immunization program.
2. Description of the ACCD’s mandate, structure and
procedures
Open access under CC BY-NC-ND license2.1. The overall role and mandate of the ACCD
The Advisory Committee on Communicable Diseases, estab-
lished in the mid-1960s, is responsible for reviewing the status of
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The minutes of both types of sessions are circulated to all ACCD
members at least two weeks before the next meeting. However,P.R. Wijesinghe et al. / V
ommunicable diseases – both vaccine-preventable and those for
hich there are no vaccines – on a regular basis and for making
ll legally binding policy decisions related to their control and pre-
ention in the country [6]. All policy decisions related to the NPI in
he prevention and control of vaccine-preventable diseases come
nder the purview of the ACCD. Although themandate of the ACCD
as been described in several documents, the Committee does not
ave formal terms of reference either written in a public document
r in documents given to its members.
.2. Structure and composition of the Committee
The Quarantine and Prevention of Diseases Ordinance of 1897
7], is the legal basis for the ACCD, though the act does not specif-
cally mention the establishment of such a committee. The ACCD
onsists of a Chairperson, a Secretary and 36 other members. The
irector General (DG) of Health Services is always the Chairper-
on of the Committee and the Chief Epidemiologist – who heads
he Epidemiology Unit, under which the NPI is managed – serves,
y designation, as the ACCD Secretary. The Secretary convenes the
CCD, prepares the agenda for the meetings, and is responsible for
pdating members on progress in the national implementation of
he Committee’s previous recommendations.
The other members of the ACCD consist of academics and
xperts in a range of disciplines related to communicable dis-
ases, including epidemiology; pharmacology; pharmacovigilance;
accinology; immunology; and speciﬁc infectious diseases of
mportance to Sri Lanka, such as malaria, dengue, leprosy, ﬁlari-
sis, HIV/AIDS, and tuberculosis. In addition, there are members
ith expertise in health education, community medicine, mater-
al and child health, family health, general practice, paediatrics,
icrobiology, quarantine services, national drug regulation, med-
cal logistics, and health administration. However, there are as
et no members with expertise in economics on the Commit-
ee. All experts should be either board-certiﬁed consultants in
heir respective ﬁelds, with a Ph.D. or MD degree or high-level
ealth administrators in designated ministerial positions (e.g., the
eputy Director General of Health Services) to qualify formember-
hip.
The public sector is represented on the ACCD by members from
elevant agencies anddepartmentsof theMinistryofHealth (MOH),
s well as from public universities. Members of relevant indepen-
ent professional organizations, which consist of both public and
rivate sector professionals, such as the colleges of paediatricians,
icrobiologists and community medicine, represent the interests
f their organization on the Committee.
In addition, two Committee seats are always allotted to repre-
entatives of the World Health Organization (WHO) and UNICEF,
s key international partners in immunization. While the roles
nd responsibilities of these members are the same as for other
embers, they are also entrusted with the task of coordinating
xternal ﬁnancial and technical support through their agencies,
hen requested to do so by the ACCD.
Membership slots on the Committee are allocated to both des-
gnated posts and to selected agencies and organizations. In the
bsence of formal terms of reference, the Chairperson determines
hich expertise will be represented on the Committee, in con-
ultation with other ACCD members. He then ofﬁcially invites
fﬁcials in certain Ministry of Health posts designated as ACCD
embers to join the Committee. These ministry ofﬁcials remain
n the Committee for as long as they remain in their jobs, after
hich the successor in their post replaces them on the Committee.
he Chairperson also invites academic institutions, local organi-
ations, professional associations and WHO and UNICEF (United
ations Children’s Fund) to nominate suitable candidates for the
ommittee. These groups, which are free to nominate new rep-28S (2010) A96–A103 A97
resentatives to the Committee from time to time, use different
methods for selecting their nominees, ranging fromvoting, to form-
ing a committee to nominate a person onbehalf of the organization,
to selecting the candidate with the most expertise, to choosing the
most senior staff person, since membership on the ACCD is consid-
ered prestigious.
Unlike in some industrialized countries, there are no repre-
sentatives on the ACCD from health sector trade unions, the
pharmaceutical industry, or consumer groups. The Committee also
does not have ex-ofﬁcio (non-voting)members. However, the ACCD
allows any external observer, including those from the above sec-
tors, to participate in meetings upon request, subject to approval
by the Chairperson. These observers cannot participate in decision-
making. In addition, theCommittee is allowed to invite any relevant
specialist as an external observer to give a brieﬁng, make recom-
mendations or participate in discussions on an issue of concern to
the ACCD. Any individual, in his or her ofﬁcial capacity or as a citi-
zen, may forward comments, grievances, or suggestions in writing
to the ACCD to discuss during meetings.
2.3. Conﬂicts of interest
Given the substantial ﬁnancial implications that recommenda-
tions of national advisory committees on immunization practices
may have for the public and private sectors, as well as for vaccine
manufacturers, candidates who are nominated for membership
on immunization advisory committees in industrialized coun-
tries undergo careful screening for potential conﬂicts of interest
before their names are submitted for ﬁnal consideration. To ensure
the integrity of the Committee in these countries, all nominees
are reviewed by a steering committee [8]. This practice does
not yet exist, however, in Sri Lanka. Considering the relative
scarcity of experts and the ﬁnancial constraints in the country,
it is possible that some Committee members may also serve on
boards of vaccine production companies, provide consulting or
advisory services to them, or accept honoraria or travel reim-
bursement from a vaccine manufacturer to attend seminars or
symposia.
2.4. Procedures of meetings
The ACCD has regularly scheduled quarterly meetings, as well
as emergency meetings to address urgent or priority issues. The
agenda of the quarterly meetings includes a discussion of issues
remaining from the previousmeeting, a situation update on immu-
nization and priority communicable diseases in the country, and
a review of the implementation and effectiveness of current
prevention and control strategies, including recently enacted rec-
ommendations. The agenda also includes new issues related to
communicable diseases and immunization. Time is allocated to
discuss any other matter, as well as correspondence from outside
agencies or individuals. The sessionsmay include technical presen-
tations by relevant experts, event-based surveillance reports from
various sources, research study ﬁndings, ﬁeld supervision reports,
AEFI investigations, or disease outbreak reports. In contrast, the
agenda of emergency sessions is limited to a discussion of speciﬁc
issues.unlike in many industrialized countries, the meeting minutes are
not accessible to the general public in either print form or online,
nor are they ofﬁcially available to anyone other than ACCD mem-
bers. The minutes are provided to observers for the sessions that
they attend.
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.5. Areas that the ACCD addresses
Unlike advisory committees on immunization practice in many
ountries, the mandate of the ACCD goes beyond vaccines, to
nclude providing guidance on all types of communicable diseases
nd interventions for their control (Fig. 1). In addition to addressing
accine-preventable diseases, the Committee deals with prior-
ty infectious diseases such as dengue, leptospirosis and malaria.
or example, the ACCD approved the decision to integrate lep-
osy services provided by a centralized, vertical program into the
eneral health services, once the prevalence of the disease was
educed to elimination level. And during a leptospirosis outbreak
n 2008, the ACCD approved chemoprophylaxis with doxycycline
or selected high-risk groups. In addition, the Committee has
pproved new guidelines for treatment of malaria and is cur-
ently assessing the feasibility of using bio-larvicides to control
engue.
In the rest of this paper, we focus on the areas that the ACCDddresses in regards to vaccines and immunization.
.5.1. Disease surveillance
Staff of the Epidemiology Unit of the MOH use Sri Lanka’s well-
unctioning passive disease surveillance system as well as special
Fig. 1. Areas and types of decision28S (2010) A96–A103
surveillance systems for speciﬁc diseases [9] to assess the situation
regarding vaccine-preventable diseases and to recommend action.
With the evolving communicable disease proﬁle in the country, the
need sometimes arises to add new diseases to the disease surveil-
lance system to facilitate decision-making. TheACCDmust approve
anyadditions to the list ofnotiﬁablediseasesbeforeofﬁcial notiﬁca-
tion of the amended list is sent out in a bulletin.Mumps,meningitis
and varicella are recent examples of diseases that have been added
to the disease surveillance system,with approval from the ACCD, in
order to inform future decisions about new vaccines against these
diseases.
2.5.2. New vaccine introduction
TheACCD approves the introduction of any newvaccine into the
NPI, after being presentedwith evidence related to disease burden,
the vaccine’s efﬁcacy, cost-effectiveness and other relevant data. In
the past few years, the ACCD has examined such evidence to rec-
ommend the introduction of the live Japanese encephalitis vaccine,
SA 14-14, as a low cost, safe and effective alternative to the inac-
tivated mouse-brain derived JE vaccine that was being used in the
national program, as well as the introduction of the DPT-hepatitis
B-Hib vaccine, which took place with Global Alliance for Vaccine
and Immunization (GAVI) support.
s that the ACCD deals with.
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.5.3. Immunization strategies
Reviewing existing immunization strategies is another func-
ion of the ACCD. For example, following a large measles outbreak
hat occurred from October 1999 to November 2000 in Sri Lanka,
he ACCD approved the recommendation of the Epidemiology
nit to initiate a country-wide measles catch-up campaign and
o add a second measles dose to the immunization schedule in
he form of measles–rubella (MR) vaccine at the age of three
ears. Similarly, the decision to conduct National Immunization
ays (NIDs) and Sub-National Immunization Days (SNIDs) for polio
radication was supported by the ACCD. Following the mass dis-
lacement of people in the recently concluded civil war, the ACCD
ook timely measures to approve immunization guidelines for
he internally displaced population. Immunization guidelineswere
lso developed for victims of the Asian tsunami that occurred
n 2004.
.5.4. Addressing immunization-related safety concerns
The ACCD foresees impending threats to the NPI and suggests
easures to overcome them. Following the death in 2009 due to
naphylaxis of a child who had just received rubella vaccine, the
ommittee recommended an island-wide training on the detection
ndearlymanagement of anaphylaxis forMedical andNursingOfﬁ-
ers who provide vaccination services in outreach clinics, with the
upport of anaesthesiologists. The Committee also decided to have
mergency kits for themanagement of anaphylaxis delivered to all
mmunization clinics in the country.
On certain occasions, the ACCD recommends new legal require-
ents. One example was the recent recommendation to make the
erformance of post-mortems for vaccine-related deaths compul-
ory in order to determine the deﬁnitive cause of death.nued ).
In addition, the Committee has recommended that the Epi-
demiology Unit, in collaboration with the Directorate of Private
Sector Health Development of the MOH, start working closely
with private sector institutions to improve immunization ser-
vices, cold chain maintenance and AEFI reporting in the private
sector.
On occasion, the ACCD hasmade recommendations to withhold
vaccines temporarily or permanently from the NPI for safety rea-
sons, as well as recommendations to reintroduce them following
investigations. In 2008, the Committee recommended that the NPI
suspend the introduction of the DPT-hepatitis B-Hib vaccine, fol-
lowing several cases of hypotonic hypo responsive episodes (HHE),
which resulted in ﬁve deaths [10]. Rubella vaccine was also placed
on hold for a brief period, following a series of suspected cases
of hypersensitivity among vaccine recipients and one death. Rec-
ommendations to reintroduce both the DPT-hepatitis B-Hib and
rubella vaccines after independent investigations were also made
by the ACCD [11]. The reassurance resulting from the Committee’s
recommendations to the panicked public, the media and resistant
trade unions has helped restore the public’s conﬁdence in these
vaccines, as well as the credibility of the NPI.
To dealwith such cases,which have started to negatively impact
the NPI, the ACCD approved the establishment of an Expert Com-
mittee onAEFI. This sub-committeehas becomea critical armof the
ACCD indetermining the role of vaccines in reported cases of severe
AEFI and inmaking recommendations to minimize adverse events.
The sub-committee analyzes reported cases of severe adverse
events and deaths possibly linked to vaccination, initiates further
detailed investigations, reviews these investigation reports as well
as independent investigations, and issues appropriate recommen-
dations.
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As an example, during the recent spate of deaths among recip-
ents of DPT-hepatitis B-Hib vaccine, an emergency session of the
CCD was convened to determine how to address the continued
ccurrence of deaths and cases of severe AEFI. The ACCD assigned
he Expert Committee on AEFI the task of conducting an assess-
ent of all deaths and cases of severe AEFI that were temporally
ssociated with the DPT-hepatitis B-Hib vaccine and that had been
rimarily investigated byNPImanagers. For exceptionally complex
ases, members from the AEFI Expert Committee conducted ﬁeld
nvestigations to determine causality. The Expert Committee ﬁrst
ecommended that the current batch of vaccine be replaced with
new batch, in case the adverse events were due to the particular
atch being used. These recommendations were carried out, but
s more surveillance data came in showing the continued occur-
ence of adverse events among childrenwho had received vaccines
rom the second batch, the Expert Committee recommended to the
CCD that the vaccine bewithdrawn from the program until a ﬁnal
etermination could bemade about the role of the vaccine in these
dverse events. The ACCD approved these recommendations—a
ecision that was not easy to make as opinions among Commit-
ee members were divided. Finally, based on majority opinion,
he ACCD approved the recommendation to revert back to the old
chedule of givingDPT andhepatitis B as separate vaccines,without
he Hib vaccine, for the time being.
In special circumstances like the DPT-hepatitis B-Hib vaccine
ssue, the ACCD requests external technical assistance to inform
ecommendations. WHO, for instance, was invited to carry out an
ndependent assessment of causality in the DPT-hepatitis B-Hib
nd rubella vaccine incidents. The WHO assessment provided an
nbiased, second opinion for the Committee to consider. The Com-
ittee discussed the ﬁndings from both the Expert Committee on
EFI and the WHO assessments – both of which found no con-
lusive evidence that the DPT-hepatitis B-Hib vaccine caused the
eaths – before recommending that the NPI reintroduce the vac-
ine. Though the decision was not unanimous, the discussions that
ook place between the Expert Committee on AEFI and WHO fur-
her strengthened the capacity of the ACCD to arrive at practical,
vidence-based conclusions regarding the future course of action
or this vaccine. A similar processwasused to respond to the rubella
ncident, which helped the ACCD to counter the widely held belief
mong the public and health worker trade unions that it was not
naphylaxis but the inferior quality of the vaccine that caused the
eath of the child.
.5.5. Health system improvements
The ACCD can also recommend health system improvements
hat will help ensure the success of immunization and other dis-
ase control measures. As demonstrated during the DPT-hepatitis
-Hib incident, one drawback in investigating deaths among vac-
ine recipients in Sri Lanka was the absence of a deﬁnitive cause of
eath, even for deaths inwhich postmortems had been performed.
his was attributed to the fact that Judicial Medical Ofﬁcers (JMOs),
orensic experts who perform autopsies and determine cause of
eath in homicide cases, conducted these post mortems, but had
ot been trained to look for pathological causes. The ACCDwas able
o rectify this by mandating that consultant JMOs use a standard-
zed autopsy protocolwhen conducting postmortemexaminations
f all deaths suspected to be immunization-related.
. The process of making recommendations related to the
ntroduction of new vaccines.1. Data requirements
A summary of the data required and questions to be answered
efore the ACCD makes a recommendation about a new vaccine is
hown in Fig. 2.Fig. 2. Required data and considerations of the ACCD inmaking decisions about the
introduction of a new vaccine.
To formulate policy recommendations regarding the introduc-
tion of new vaccines, the ACCD requests a set of data from the
Epidemiology Unit. The Unit then appoints a working group, con-
sisting of experts fromMinistry ofHealth agencies,major hospitals,
universities and the private sector, to help gather and analyze rel-
evant data concerning the disease and vaccine in question. The
Epidemiology Unit may also request technical or ﬁnancial support
from international partners for the collection or analysis of data,
in the form of, for instance, an expert, such as a health economist,
ﬁnancing to conduct a local clinical trial, or laboratory training for
surveillance studies.
The compilation of data on the burden of the disease in ques-
tion in Sri Lanka is a necessity before the ACCD can approve the
introduction of any new vaccine. For certain diseases, the existing
disease surveillance systemprovides sufﬁcientdata,while formany
new vaccine-preventable diseases for which local epidemiologi-
cal information and surveillance mechanisms are inadequate, the
ACCD recommends that methodologically sound disease burden
studies be conducted in the local population. The study of invasive
Hib disease conducted in Colombo district with ﬁnancial assistance
from the Hib Initiative provided critical support to the ACCD in its
decision to recommend the introduction of Hib vaccine into theNPI
in 2008. The Committee also commissioned the Epidemiology Unit
to conduct local disease burden studies of human papillomavirus
(HPV) (with ﬁnancial support from UNFPA), invasive pneumococ-
cal disease (with support from GAVI’s PneumoADIP), and rotavirus
(with support from the International Vaccine Institute (IVI)), to
inform decisions about the introduction of these vaccines in the
future.
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Data on appropriate vaccines, their immunogenicity, efﬁcacy
nd safety proﬁles are also required by the ACCD before recom-
ending the introductionof anewvaccine. As a governmentpolicy,
he ACCD will approve only WHO pre-qualiﬁed vaccines for use
n the NPI. As such, they demand methodologically sound, credi-
le vaccine efﬁcacy and safety data from other countries, and it is
he duty of the epidemiologists as managers of the NPI to provide
he Committee with this information. In addition, in recent years,
he ACCD has required that safety and immunogenicity studies
or some new vaccines be conducted in the Sri Lankan popula-
ion before a recommendation for their introduction can be made.
efore the Committee would make a decision to replace the inacti-
ated mouse-brain JE vaccine with the live, low cost SA 14-14-2
accine from China, it recommended that a study to assess the
afety and immunogenicity of the vaccine be carried out among
ri Lankan children. While the ACCD realizes that conducting local
tudies delays the introduction of a new vaccine and incurs addi-
ional costs, it felt compelled to recommend this study because of
cepticism in the medical community about existing data on the
afety and immunogenicity of the live JE vaccine. The Committee
ecommended the switch to the live vaccine in 2009 based on the
ositive results of the local study.
Since the NPI is mainly a self-funded program with many com-
eting priorities, its managers have started to look at results of
conomic analyses of new vaccines before making decisions about
heir introduction, with the support of external economists (e.g.,
romuniversities). A cost-effectiveness studywas conductedbefore
ntroducing the live JE vaccine, and a similar study is underway
or the pneumococcal conjugate vaccine, while another has been
lanned for rotavirus vaccine. In addition, NPI staffs assess the
nancial sustainability of introducing any proposed new vaccine,
xaminingoptions for ﬁnancing available through the FinanceMin-
stry and donor agencies. In seeking possible funding sources, they
lso calculate potential cost savings from reducing vaccinewastage
hrough implementation of an open vial policy, by switching to
ower cost vaccines (e.g., from the mouse-brain derived to the live
E vaccine), or other cost saving measures. As an MOH policy, the
CCD will not recommend that a vaccine be introduced into the
PI if the country cannot sustain its ﬁnancing, even if co-ﬁnancing
through GAVI) or full donor support are available for a limited
eriod of time. Therefore, the situation never arises in Sri Lanka
n which the ACCD makes a recommendation that the Ministry of
inance determines is not ﬁnancially feasible.
.2. The annual Immunization Stakeholders’ Forum
Since different professionals may hold different views regard-
ng whether and how a new vaccine should be introduced, and
ince their opinions can be critical to the success of the vaccine’s
ntroduction, the next step, after data are gathered and analyzed
y a working group, is to discuss the introduction of the vaccine
t an annual Immunization Stakeholders’ Forum. The purpose of
he Forum is to seek a wider, national consensus on the decision to
ntroduce the new vaccine and to identify potential areas of con-
ern and obstacles to its introduction. The Forum is attended by
dministrators and technical experts from the Ministry of Health
nd academia, aswell as representatives fromprofessionalmedical
rganizations, the national drug regulatory authority and interna-
ional agencies, such as WHO and UNICEF.
The Forum consists of several sessions on global advances in
accines, and for any new vaccine under consideration, there are
resentations on a needs assessment for the vaccine, economic
onsiderations, and proposed vaccination strategies. The presenta-
ionsare followedbypaneldiscussions,workinggroupsessionsand
roup presentations. The Forum concludes with a plenary discus-
ion, duringwhich a consensus is reachedon the introductionof the28S (2010) A96–A103 A101
vaccine into the NPI. On occasion, Forum participants recommend
that a new working group be formed to gather additional evidence
and analysis about particular concerns and issues raised during the
meeting. If the Forum recommends the introduction of the vaccine,
NPImanagers thendevelop the strategies to introduce thenewvac-
cine into the program. Once these recommendations are made by
the Immunization Stakeholders’ Forum, they are submitted to the
ACCD for approval.
3.3. Deliberations of the ACCD
All of the steps involved in considering the introduction of a
new vaccine, including the collection and analysis of data and the
holding of the annual Forum, simplify the decision-making pro-
cess for the ACCD. However, even at this stage, the Committeemay
appoint a new working group to further clarify important issues
regarding, for instance, the epidemiology of the disease, the type
of vaccine, or its safety proﬁle. The sessions of the ACCD are always
interesting, with heated arguments and counter arguments made
by clinicians and academics on the one hand, and epidemiologists
and health administrators on the other. Following these discus-
sions, which can last several hours, the analysis and presentations
of the working groups, and a discussion of their recommendations,
the ACCD reaches a consensus on its position regarding introduc-
tion of the new vaccine, as opposed to taking a vote, as in some
countries [12]. The Committee may recommend that the vaccine
be introduced universally (throughout the country), be targeted
for high-risk populations only, or that the introduction be phased
in. The Committee may also recommend that the vaccine not be
introduced at this time.
3.4. Implementation of ACCD recommendations
Once theCommittee reaches a consensus on a recommendation,
these recommendations become legally binding for theMinistry of
Health. The Deputy Director General (Public Health), on behalf of
the DG of Health Services, oversees the implementation of these
recommendations. The MOH then prepares guidelines, based on
these recommendations, which are disseminated to relevant min-
istry ofﬁcials and health workers in the form of a government
circular. Once the recommendations are published in the circular,
all health ofﬁcials – at both the national and provincial levels –
are obligated to implement them. The Regional Directors of Health
Services are responsible for the technical implementation of the
guidelines at the local level. ACCD recommendations that require
changes in the law must be approved by the cabinet before being
implemented. Papers are prepared and submitted to the Cabinet of
Ministers through theMinister of Health for approval. Legal ofﬁcers
of the MOH liaise with the Attorney General’s ofﬁce to plan their
implementation.
The ACCD also follows the progress in implementing its rec-
ommendations and any issues that have arisen in subsequent
meetings.
4. Factors inﬂuencing decisions about vaccines and the
immunization program
Immunization is consistent with the national policy in Sri Lanka
of universal free health care for all [5,13] and has been identiﬁed
as a priority area for investment [4]. These social and ﬁscal gov-
ernment policies are positive factors inﬂuencing decisions about
vaccinations and the immunization program. At the same time,
political and societal pressure is mounting on government health
ofﬁcials concerning immunization-related matters, given that pol-
icymakers, trade unions and the public consider the NPI a precious
asset and the pride of the nation that should be protected and
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reserved at any cost [14]. As a result, while the policies of succes-
ive governments have been instrumental in making the national
mmunization program a success [13,15], the active and critical
ole played by opposition political parties and health worker trade
nions have inﬂuenced the decision-making process and have
elped improve the quality of the program.
For example, following the death from anaphylactic shock of a
chool girl who had just been vaccinated against rubella in 2009,
ealth worker trade unions demanded that the date of manufac-
ure, along with the expiry date, be printed on all vaccine vials
sed by the public sector in Sri Lanka, even though WHO labelling
uidelines do not require this. The ACCD subsequently made a
olicy recommendation that all future vaccines used in the NPI
ust carry the date of manufacture and the expiry date on the vial
tself. In addition, after two separate incidents of death following
ubella vaccination, opposition parties raised questions about the
ransparency of vaccine procurement, and representatives of the
CCDwere summoned before a parliamentary select committee to
nswer their queries. The inﬂuence of political parties has there-
ore made the decision-making process for immunization more
ransparent and accountable in Sri Lanka.
In addition, in recent years, intensive media interest and cov-
rage (both print and electronic) have dramatically inﬂuenced
he decision-making process related to immunization and have
ed to changes in the implementation of the immunization pro-
ram. Following the death from anaphylaxis mentioned above, the
edia brought into focus the lack of anaphylaxis management kits
t health clinics and the absence of a Medical Ofﬁcer or Nurse
uthorized to administer drugs to manage anaphylaxis. This media
ttention and the resulting national dialogue led the ACCD to rec-
mmend that all guidelines related to immunization of children at
linics be revised, to stipulate which personnel must be present
uring vaccination sessions and to require that all health clinics
arry anaphylaxis management kits. The ACCD also mandated new
tricter and more transparent procedures for the procurement of
accines.
The availability of technical support for evidence-based
ecision-making and funding from non-traditional sources, such
s the GAVI Alliance, GAVI’s accelerated vaccine development and
ntroduction programs (e.g., the Hib Initiative, the Rotavirus Vac-
ine Program, PneumoADIP), UNFPA and others, have also played a
ital and praiseworthy role in inﬂuencing the national immuniza-
ion program [16].
The ever-expanding role of the nation’s primaryhealth care staff
n improving the national AEFI surveillance system has also led
o an increased focus among immunization program managers on
mmunization safety and evidence-based decision-making related
o vaccination safety issues. Finally, one cannot underestimate the
mportant role of literate, vigilant parents in the success of the
mmunization program by having their children immunized on
ime and accepting the newly introduced vaccines.
. Remaining issues, challenges and potential solutions
Growing public concerns about vaccines in Sri Lanka have
ncreased the need to rely on evidence and to be transparent at
very step, from gathering data to monitoring vaccine side effects
t the local level. Participatory decision-making in the ACCD and
n the Immunization Stakeholders’ Forums has been used to make
nformed decisions about which new vaccines to introduce and to
aintain the credibility of the NPI. However, there are still some
reas that need further improvement in the long term.
One area is the lack of formal written terms of reference for the
CCD, as exist inmany countrieswith vaccine advisory committees
12]. It is appropriate and timely that written terms of reference28S (2010) A96–A103
for the ACCD be prepared and made public. In addition, though
transparency is enhanced by having representation of a range of
stakeholders, the public has not shown much interest in following
the decision-making process and has not demanded access to its
proceedings. However, the media has played a major role in ques-
tioning the validity of decision-makingwhen the safety of a vaccine
has been in question. This has led program managers to sensitize
the media prior to any changes in the EPI schedule or the intro-
duction of a new vaccine. Making proceedings of ACCD meetings
accessible to the public, including the media, is therefore worth
considering for the future to ensure transparency and to pre-empt
misinformation or the spread of rumours.
Similarly, since trade unions in the health sector have signif-
icant inﬂuence in health-related matters due to their bargaining
power, mechanisms are also needed to ensure that they are prop-
erly informed of the decision-making process related to the NPI.
These measures can include organizing meetings with trade union
representatives to discuss a new ACCD decision and reporting back
to the ACCD on their concerns. Representatives of trade unions
shouldalsobemademoreawareof the fact that they canparticipate
as external observers in ACCD meetings upon request.
While ACCD membership now includes a wide range of experts
and stakeholders, health economists should be included on the
Committee to ensure that ﬁnancial and economic aspects of immu-
nization are considered systematically. At present, many economic
studies are conducted because of the personal interest of a hand-
ful of epidemiologists, with support from international health
economists. The lack of health economists in Sri Lanka is a key
obstacle to their inclusion on the ACCD; however, this situation
should improve over time if postgraduate courses on Community
Medicine add a health economics module to its curriculum and
if post-doctoral community medicine trainees are encouraged to
study health economics during their mandatory training overseas.
It is widely recognized that having ACCDmembers declare con-
ﬂicts of interest is critical to ensure transparency in the eyes of
the general public [17], especially given the mounting criticism
of doctors having ﬁnancial interests in pharmaceutical companies,
including those that produce vaccines [18]. Since the ACCD has, at
present no rules regarding conﬂict of interest, it is advisable that
conﬂict of interest guidelines be developed and implemented in the
future.
6. Conclusion
In conclusion, as inmanydeveloped countries, Sri Lankahaswit-
nessed in recent years a growing reluctance among some people to
accept vaccines, a similar scepticism among some in the medical
profession – due to rare adverse events and a low incidence or even
disappearance of EPI-targeted diseases [19] – and aggressive, neg-
ative media campaigns that question the credibility of its national
immunization program. Despite the limitations mentioned above,
the ACCD has risen to these challenges by broadening its repre-
sentation to include a range of stakeholders, and by being more
transparent in its decision-making. This processwill further evolve,
and the adaptability of the Committee to changing situations will
determine the future success of the NPI and its contribution to the
national development of Sri Lanka.
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